Volume 19, Number 11—November 2013
Research
CTX-M β-Lactamase–producing Klebsiella pneumoniae in Suburban New York City, New York, USA
Guiqing Wang
, Tiangui Huang, Pavan Kumar Makam Surendraiah, Kemeng Wang, Rashida Komal, Jian Zhuge, Chian-Ru Chern, Alexander A. Kryszuk, Cassidy King, and Gary P. Wormser
, Tiangui Huang, Pavan Kumar Makam Surendraiah, Kemeng Wang, Rashida Komal, Jian Zhuge, Chian-Ru Chern, Alexander A. Kryszuk, Cassidy King, and Gary P. Wormser
Table 3
Selected clinical/epidemiologic features of the 25 patients with CTX-M ESBL–producing K. pneumoniae from New York, USA and certain microbiological characteristics of the isolates*
| Year | Isolate | Patient age, y | Sex | Source | ≤72 h of admission | Prior hospital admission† | Prior ESBL KP/E. coli† | LOS, d‡ | Disk diffusion (mm) |
MIC (μg/mL) |
β-lactamase(s) | PFGE type (n = 17) | ST type (n = 18) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX | CAZ | CTX | CAZ | ||||||||||||
| 2009 | T76 | 93 | M | Urine | N | Y | N | 11 | 9 | 18 | >256 | 8 | CTX-M-15, SHV-28, TEM-1 | PF5 | 15 |
| PK114 | 72 | F | Urine | Y | Y | N | 5 | ND | ND | ND | ND | CTX-M-15, SHV-11, TEM-1 | ND | 437 | |
| 2010 | KF351 | 24 | M | Urine | N | Y | N | 7 | 8 | 21 | >256 | 3 | CTX-M-2, SHV-11, TEM-1 | PF6 | 792 |
| KF403 | 71 | F | Urine | Y | Y | Y/Y | 10 | 6 | 13 | >256 | 32 | CTX-M-15, SHV-11, TEM-1 | PF6 | 437 | |
| KF548 | 31 | M | Blood | N | Y | N | 20 | 10 | 15 | >256 | 16 | CTX-M-15, SHV-27, TEM-1 | PF1 | 280 | |
| KF563 | 57 | M | Respiratory | N | Y | Y | 20 | 6 | 6 | >256 | 96 | CTX-M-15, SHV-28, TEM-1 | PF2 | 15 | |
| KF602 | 70 | M | Urine | N | N | N | 3 | 8 | 14 | 128 | 12 | CTX-M-15, SHV-11, TEM-1 | PF7 | 17 | |
| PK6 | 71 | M | Respiratory | N | Y | N/Y | 4 | ND | ND | ND | ND | CTX-M-3, SHV-11, TEM-1 | ND | ND | |
| 2011 | KG318 | 64 | F | Urine | Y | Y | Y | 8 | 6 | 12 | >256 | 64 | CTX-M-15 | PF8 | ND |
| KG291 | 67 | M | Urine | N | N | N | 19 | ND | ND | ND | ND | CTX-M-15, SHV-11, TEM-1 | ND | ND | |
| KG304 | 44 | F | Urine | Y | Y | Y | 21 | 6 | 9 | >256 | 32 | CTX-M-15, SHV-1, TEM-1 | PF8 | 252 | |
| KP33 | 71 | F | Urine | N | Y | N | 13 | 10 | 17 | >256 | 8 | CTX-M-15, SHV-1, TEM-1 | PF3 | 16 | |
| KP38 | 69 | M | Urine | Y | Y | N | 7 | 10 | 19 | >256 | 6 | CTX-M-1, SHV-11 | PF3 | 11 | |
| KP34 | 62 | M | Urine | Y | Y | Y | 12 | 13 | 22 | 32 | 3 | CTX-M-15, SHV-11 | PF5 | 147 | |
| KP41 | 7 | F | Wound | Y | Y | N | 1 | 6 | 18 | >256 | 12 | CTX-M-15, SHV-1, TEM-1 | PF4 | ND | |
| KP35 | 39 | F | Urine | Y | N | N | 1 | 6 | 13 | >256 | 32 | CTX-M-15, SHV-11 | PF5 | 392 | |
| KP37 | 44 | M | Blood | Y | Y | N | 5 | 6 | 10 | >256 | 48 | CTX-M-15, SHV-1 | PF4 | 15 | |
| PK23 | 15 | M | Respiratory | Y | N | N | 5 | 10 | 18 | 128 | 6 | CTX-M-15, SHV-11, TEM-1 | PF4 | 48 | |
| PK30 | 62 | F | Respiratory | N | N | N | 26§ | 9 | 8 | >256 | 16 | CTX-M-3, SHV-11, TEM-1 | PF3 | ND | |
| PK107 | 71 | F | Blood | N | N | N | 90§ | 8 | 8 | >256 | >256 | CTX-M-3, SHV-11, TEM-1 | PF3 | 11 | |
| 2012 | PK133 | 52 | M | Urine | Y | Y | N | 90 | 6 | 15 | 128 | 24 | CTX-M-15, SHV-11 | ND | ND |
| PK135 | 81 | F | Urine | N | N | N | 14 | 11 | 20 | 64 | 6 | CTX-M-3, SHV-11, TEM-1 | ND | 11 | |
| PK140 | 66 | F | Urine | Y | Y | N/Y | 7 | 7 | 15 | >256 | 16 | CTX-M-15, SHV-11 | ND | 392 | |
| CK17 | 34 | F | Urine | Y | N | N | 26 | 16 | 8 | 16 | >256 | CTX-M-15, SHV-12 | ND | 258 | |
| CK30 | 53 | M | Wound | N | N | N | 77 | 6 | 15 | >256 | 48 | CTX-M-15, SHV-1, TEM-1 | ND | nd | |
*ESBL, extended-spectrum β-lactamase; ; CTX: cefotaxime; CAZ: ceftazidime; PFGE, pulsed-field gel electrophoresis; ST, sequence type; Y, yes; N, noND, not determined.
†Prior hospitalization or history of recovering ESBL K. pneumoniae (KP) and E. coli isolate within 8 mo of the current admission.
‡LOS, length of stay after the recovery of CTX-M K. pneumoniae.
§Patients died.
Page created: October 31, 2013
Page updated: October 31, 2013
Page reviewed: October 31, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.